Results 111 to 120 of about 15,380 (223)

A current perspective on stereotactic body radiation therapy for pancreatic cancer. [PDF]

, 2016
Pancreatic cancer is a formidable malignancy with poor outcomes. The majority of patients are unable to undergo resection, which remains the only potentially curative treatment option.
Czito, Brian G, Hong, Julian C, Palta, Manisha, Willett, Christopher G   +3 more
core   +2 more sources

Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges

World Journal of Gastroenterology, 2019
Pancreatic cancer is one of the leading causes of cancer death worldwide. Adjuvant chemotherapy has been developed based on the experiences made with palliative chemotherapy, and advocated to improve long-term survival of patients with this disease. However, the optimal chemotherapeutic regimen remains controversial. Recently, Conroy et al demonstrated
Yang, Feng, Jin, Chen, Fu, De-Liang, Warshaw, Andrew L   +3 more
openaire   +2 more sources

Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticles [PDF]

, 2019
Over 95% of pancreatic adenocarcinomas (PDACs), as well as a large fraction of other tumor types, such as colorectal adenocarcinoma, are driven by KRAS activation. However, no direct RAS inhibitors exist for cancer therapy.
Bi, Ye, Brooks, Candace, DeNardo, David G, Fields, Ryan C, Fleming, Timothy, Gillanders, William E, Goedegebuure, S Peter, Hawkins, William G, Krasnick, Bradley A, Pan, Hua, Sankpal, Narendra, Strand, Matthew S, Wetzel, Christopher, Wickline, Samuel A, Zhang, Xiuli   +14 more
core   +1 more source

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial [PDF]

, 2017
BACKGROUND: The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients with resected pancreatic cancer.
Akaike, Alan Anthoney, Alec McDonald, Bengt Glimelius, Campbell, Capello, Christopher M Halloran, Conroy, Cox, Cunningham, Daniel H Palmer, David Borg, David Cunningham, David Sherriff, Derek A O'Reilly, Eftychia E Psarelli, Gary William Middleton, Greenhalf, Harpreet Wasan, Henderson, Jakob R Izbicki, John P Neoptolemos, Jonathan Wadsley, Juan W Valle, Kinnari Patel, Kleeff, Liao, Markus W Büchler, Neoptolemos, Neoptolemos, Neoptolemos, Neoptolemos, Neoptolemos, Oettle, Olusola Faluyi, Pascal Hammel, Paul J Ross, Paula Ghaneh, Pehr Lind, Peto, Peto, Reni, Richard Jackson, Roopinder Gillmore, Rubin Soomal, Schemper, Schoenfeld, Sebastian Cummins, Sharmila Sothi, Sinn, Stephen Falk, Sultana, Suzanne Darby, Thilo Hackert, Tim Meyer, Tom Crosby, Trotti, Uesaka, Valle, Vivaldi, Von Hoff, White, Yuk Ting Ma   +62 more
core   +6 more sources

FOLFIRINOX in Advanced Pancreatic Cancer, NEMROCK Experience

Cancer and Oncology Research, 2014
Purpose: The objectives of study are to evaluate efficacy and toxicity of combination chemotherapy FOLFIRINOX in Egyptian patients with inoperable or metastatic pancreatic cancer. Patients and Methods: Between September 2011 and September 2012, twenty patients with inoperable locally advanced or metastatic pancreatic adenocarcinoma were included to ...
Elghonemy E., Selim H., Sakr A., Shukur H.   +3 more
openaire   +1 more source

Attenuation of hedgehog/GLI signaling by NT1721 extends survival in pancreatic cancer. [PDF]

, 2019
BackgroundPancreatic cancer is one of the most lethal malignancies due to frequent late diagnosis, aggressive tumor growth and metastasis formation.
Horne, David A, Kowolik, Claudia M, Lin, Min, Overman, Larry E, Xie, Jun   +4 more
core   +1 more source

Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine FOLFIRINOX in advanced pancreatic cancer: a systematic review

Therapeutic Advances in Medical Oncology, 2019
Background: No clinical trial has directly compared nab-paclitaxel/gemcitabine (nab-P/G) with FOLFIRINOX (fluorouracil/leucovorin/oxaliplatin/irinotecan) in metastatic or advanced pancreatic cancer (mPC or aPC).
Elena Gabriela Chiorean, Winson Y. Cheung, Guido Giordano, George Kim, Salah-Eddin Al-Batran   +4 more
doaj   +1 more source

Characteristics and survival of older patients with metastatic pancreatic cancer: a retrospective analysis of the AC Camargo Cancer Center experience

Therapeutic Advances in Medical Oncology, 2019
Background: Advanced age is the most important risk factor for pancreatic cancer and about half of patients are diagnosed with metastatic disease. In the first-line setting, multidrug chemotherapy regimens were shown to be more effective than gemcitabine
Josenon Gomes Costa, Victor Hugo Fonseca de Jesus, Marcos Pedro Guedes Camandaroba, Aldo Lourenço Abbade Dettino   +3 more
doaj   +1 more source

PPAR-alpha: a novel target in pancreatic cancer [PDF]

, 2015
Background: Current targeted therapies in pancreatic cancer have been ineffective. The tumor stroma, including intra- and peri-tumoral inflammation and fibrosis, is increasingly implicated in pancreatic cancer.
Hua, Alexander Mach
core   +1 more source

Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting

Cancer Management and Research, 2017
Fadi Braiteh,1 Manish B Patel,2 Monika Parisi,2 Quanhong Ni,2 Siyeon Park,2,3 Claudio Faria2 1Comprehensive Cancer Centers of Nevada, University of Nevada School of Medicine, Las Vegas, NV, 2Celgene Corporation, Summit, NJ, 3The Ohio State University ...
Braiteh F, Patel MB, Parisi M, Ni Q, Park S, Faria C   +5 more
doaj